Clinicopathological Evaluation of CD44 Expression as a Proliferative Marker in Prostatic Adenocarcinoma
Iraqi Postgraduate Medical Journal,
2021, Volume 20, Issue 2, Pages 165-171
Prostatic cancer is the 6th commonest cancer worldwide, and the 2nd commonest cancer among men. In Iraq, it is the fourth most common cancer and cause of cancer deaths in males.
The commonest form of prostatic cancer is adenocarcinoma (75% of patients > 65 years). Prevalence of prostate cancer rises with age and hormonal causes. Core needle biopsy is a standard technique and largely preferred for non-operative diagnosis since it permits architectural and cytological assessment.
Immunohistochemical evaluation of CD44 expression in prostatic adenocarcinoma as a proliferative marker and correlate it with clinicopathological parameters (age, PSA level, and tumor grade).
MATERIALS AND METHODS:
Prostatic specimens were obtained via different procedures (TURP, and tru-cut biopsy). Formalin fixed paraffin embedded blocks from 50 patients with prostatic adenocarcinoma, histological sections taken for hematoxylin and eosin staining to determine histopathological features, monoclonal antibody for CD44 used for immunohistochemical staining of tissue sections and CD44 expression correlated with clinicopathological parameters (age, PSA level, and tumor grade).
There was a significant inverse correlation between CD44 expression and Gleason grade score (i.e. high expression in low grade tumors), while there was no correlation between age and PSA level with CD44 expression.
CD44 expression in prostatic adenocarcinoma can be utilized as a prognostic marker as it implies less tumor aggressiveness with positive high expression which means lower grade tumor and better differentiation.
- Global Burden of Disease Cancer Collaboration, Fitzmaurice C, Allen C, et al. Global, Regional, and National Cancer Incidence, Mortality, Years of Life Lost, Years Lived with Disability, and Disability-Adjusted Life-years for 32 Cancer Groups, 1990 to 2015: A Systematic Analysis for the Global Burden of Disease Study. JAMA Oncol. 2017;3:524.
- Iraq Cancer Board, results of Iraqi Cancer Registry, Ministry of health. Iraq Cancer Registry Centre. Baghdad - Iraq. 2016.
- Zeegers MP, Jellema A, Ostrer H. Empiric risk of prostate carcinoma for relatives of patients with prostate carcinoma: a meta-analysis. Cancer. 2003;97(8):1894-1903.
- Noone AM, Howlader N, Krapcho M, et al. SEER Cancer Statistics Review, 1975-2015. National Cancer Institute. 2015.
- Zhu C, et al. Conditional expression of the androgen receptor induces oncogenic transformation of the mouse prostate. The Journal of biological chemistry. 2011;286:33478-33488.
- Hori S, Blanchet JS, Mcloughlin J. From prostate-specific antigen (PSA) to precursor PSA (proPSA) isoforms: a review of the emerging role of proPSAs in lhe detection and management of early prostate cancer. BJU lnt. 2013;112:717-728.
- Epstein JI, Zelefsky MJ, Sjoberg DD, et al. A contemporary prostate cancer grading system: A validated alternative to the Gleason score. Eur Urol. 2015;69(3):428-435.
- Muin S, Tuffaha A, Guski H, et al. (IHC in tumor Dx). Springer international publishing. 2018.
- Leslyey J et al. "Cd44 structure and function". Frotires in Bioscience. 1998;3:616-630.
- Goldblum JR, McKenny JK, Lamps LW, et al. Rosai and Ackerman’s surgical pathology. 11th edition. Elsevier. 2018;2:52
- Kalantari E, Asgari M, Nikpanah S. Co-Expression of Putative Cancer Stem Cell Markers CD44 and CD133 in Prostate Carcinomas. Pathol Oncol Res. Springer. 2017;12253:160-169.
- Hirth CG, Dos Santos AM, de Cerqueira JBG, PanCD44 Immunohistochemical Evaluation in Prostatectomies from Patients with Adenocarcinoma. BioMed Research International. Hindawi. 2018;2018:2061-2068.
- Korski K, Malicka-Durczak A, Breborowicz j. Expression of stem cell marker CD44 in prostate cancer biopsies predicts cancer grade in radical prostatectomy specimens. Pol J Pathol. 2014;65(4):291-295.
- Noordzij MA, van Steenbrugge GJ, Verkaik NS, et al. The prognostic value of CD44 isoforms in prostate cancer patients treated by radical prostatectomy. Clinical Cancer Research. American association for cancer research. 1997;3:805-808.
- Article View: 38
- PDF Download: 60